Whitehawk Therapeutics Inc

NASDAQ:WHWK

Biotechnology

Healthcare
$3.13 +1.42%

+$0.06 today

Market cap
$184.70M
Beta
0.77
P/E (TTM)
-2.6
EPS (TTM)
-$1.67
52W Low $1.57High $5.50

Volume 0.28M

Average 0.31M

WHWK Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Whitehawk Therapeutics IncNASDAQ: WHWK

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $17.23M rose 96.1% year over year, behind the +115.1% change in trailing-twelve-month research & development. Sequentially, it fell 9.4% from the prior quarter. Over 3 fiscal years it compounded at +40.7% a year.

Context

  • Research & development amounted to 1273.1% of revenue in FY2025, up 1076.7 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +96.1% toward the trailing-twelve-month pace of +115.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$17.23M-9.4% QoQ
Last fiscal yearDec 2025
$90.96M+78.3% YoY
LTMMar 2026
$99.41M+115.1% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+96.1%——
1 year+78.3%——
3-year CAGR+40.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
90.96M USD
Year-over-year change
+78.3%
4-year CAGR
+46.6%

Research & Development vs competitors

How WHWK compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +115.1% is the highest of 9, against a peer median of -13.4%.
  • Over three fiscal years its annual growth of +40.7% compares with a peer median of +2.7%.
WHWK Competitors
Research & Development for WHWK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$135.36M USD-19.9%-12.2%86.2%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$108.76M USD-25.2%-14.7%—
WHWKWhitehawk Therapeutics IncLTM Mar 2026$99.41M USD+115.1%+40.7%—
PLRXPliant Therapeutics, Inc.LTM Mar 2026$79.04M USD-54.8%+4.0%—
CNTXContext Therapeutics Inc.LTM Mar 2026$35.41M USD+46.4%+65.0%—
OVIDOvid Therapeutics Inc.LTM Mar 2026$30.07M USD-8.9%+1.3%422.2%
IMMXImmix Biopharma, Inc.LTM Mar 2026$20.26M USD+102.3%+57.1%—
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$19.63M CAD+4.7%+15.5%—
CLNNClene Inc.LTM Mar 2026$12.86M USD-17.9%-24.0%9596.3%
Peer median (excluding WHWK) —-13.4%+2.7%422.2%

Competitors are the stored peer set for WHWK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.12M15.22M24.35M25.98M7.15M
Cost of Revenue19.67M34M51.74M54.05M760K
Gross Profit(18.55M)(18.78M)(27.38M)(28.07M)6.39M
Gross Margin-1656.3%-123.4%-112.4%-108.0%89.4%
Research & Development19.67M32.66M48.93M51.03M90.96M
Selling, General & Admin18.51M40.18M44.55M36.75M29.82M
Operating Expenses92.67M43.9M44.55M39.39M120.79M
Depreciation & Amortization105K159K169K193K79K
EBITDA(36.96M)(58.8M)(65.37M)(64.63M)(20.52M)
EBITDA Margin-3299.6%-386.4%-268.4%-248.7%-287.2%
Operating Income(111.22M)(62.68M)(71.93M)(67.46M)(114.4M)
Operating Margin-9930.1%-411.9%-295.4%-259.6%-1601.1%
Interest Income13K2.4M6.4M3.93M6.23M
Interest Expense665K230K231K154K0
Other Income / Expenses1.13M2.17M6.17M3.77M93.8M
Income Before Tax(110.09M)(60.51M)(65.77M)(63.69M)(20.6M)
Pre-Tax Margin-9829.3%-397.7%-270.0%-245.1%-288.3%
Income Tax Expense2K0000
Net Income(110.09M)(60.51M)(65.77M)(63.69M)(20.6M)
Net Margin-9829.5%-397.7%-270.0%-245.1%-288.3%
EPS (Basic)(12.41)(2.69)(2.44)(2.36)(0.33)
EPS (Diluted)(12.41)(2.69)(2.44)(2.36)(0.33)
Weighted Avg Shares8.87M22.51M26.92M27.03M61.89M
Weighted Avg Shares (Diluted)8.92M22.51M26.92M27.03M61.89M

Whitehawk Therapeutics Inc

NASDAQ:WHWK

Intrinsic Alpha fair value

Locked

Current Price

$3.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.